Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

BACKGROUND: Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The asparti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Yahya, Mansouri, Hanane, Laurent-Matha, Valérie, Alcaraz, Lindsay B., Roger, Pascal, Guiu, Séverine, Derocq, Danielle, Robin, Gautier, Michaud, Henri-Alexandre, Delpech, Helène, Jarlier, Marta, Pugnière, Martine, Robert, Bruno, Puel, Anthony, Martin, Lucie, Landomiel, Flavie, Bourquard, Thomas, Achour, Oussama, Fruitier-Arnaudin, Ingrid, Pichard, Alexandre, Deshayes, Emmanuel, Turtoi, Andrei, Poupon, Anne, Simony-Lafontaine, Joëlle, Boissière-Michot, Florence, Pirot, Nelly, Bernex, Florence, Jacot, William, du Manoir, Stanislas, Theillet, Charles, Pouget, Jean-Pierre, Navarro-Teulon, Isabelle, Bonnefoy, Nathalie, Pèlegrin, André, Chardès, Thierry, Martineau, Pierre, Liaudet-Coopman, Emmanuelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360707/
https://www.ncbi.nlm.nih.gov/pubmed/30717773
http://dx.doi.org/10.1186/s40425-019-0498-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360707/
https://www.ncbi.nlm.nih.gov/pubmed/30717773
http://dx.doi.org/10.1186/s40425-019-0498-z

Ejemplares similares